Conjugating non-canonical amino acid antibodies with click chemistry
VERAXA’s proprietary protein conjugation platform combines the concepts of genetic code expansion and highly efficient bioorthogonal click chemistry.
Current strategies for generation of ADCs are mostly based on random or site-restricted conjugation, resulting in suboptimal drug candidates.
VERAXA‘s superior protein conjugation technology with its selectable site-specific conjugation solves the most prominent challenges in antibody-drug conjugate development.
VERAXA combines optimization of conjugation site with efficient and stable conjugation chemistries. Engineering of VERAXA’s proprietary non-canonical amino acids into antibodies, on the translational level, allows precise site-specific payload conjugation at any one or multiple positions for generation of homogenous ADCs.
VERAXA’s highly efficient bioconjugation, via the fastest bioorthogonal click reaction to date, provides precise and controlled drug-to-antibody ratios with a range of variable payloads – even in vivo. Combining both cutting edge technologies in VERAXA’s ADC platform enables development of next generation ADCs with superior properties and improved therapeutic window.
Unleashing the full potential of site-specific ADCs
- Select optimized conjugation sites for best-in-class therapeutics
- Produce Homogenous ADCs with precise drug-to-antibody-ratio
- Employ efficient, convenient, and stable bioconjugation
- Modulate physicochemical properties through our variable conjugation chemistries
- Increase efficacy and safety of drug candidates for an improved therapeutic window
Introduction of our proprietary unnatural amino acids (UAAs) into our engineered antibodies enables site-specific payload conjugation on any position on the antibody, also for multiple sites. Utilizing the fastest bioorthogonal click reaction to date, our technology allows for convenient and ultrafast labeling under antibody optimal conditions – even inside cells or patients, if necessary.
The ultrafast and bioorthogonal click chemistry is the base of our antibody engineering. We are functionalizing drugs or radioisotopes with a tetrazine group. Our engineered antibodies are produced by utilizing genetic code expansion to install site-specifically an unnatural amino acid (UAA) into the antibody sequence at the translational level.
This technique enables us to produce UAA-antibodies with residue precise installation of the modification with a high batch to batch reproducibility. The modification on the antibody and the tetrazine moiety on the payload can undergo a click reaction, not only in vitro, but also for in vivo labeling this technique could be used.